Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 19
2005 39
2006 53
2007 50
2008 52
2009 55
2010 49
2011 65
2012 61
2013 62
2014 59
2015 64
2016 67
2017 60
2018 51
2019 61
2020 38
2021 25
2022 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

821 results

Results by year

Filters applied: . Clear all
Page 1
Targeting Alterations in the RAF-MEK Pathway.
Yaeger R, Corcoran RB. Yaeger R, et al. Cancer Discov. 2019 Mar;9(3):329-341. doi: 10.1158/2159-8290.CD-18-1321. Epub 2019 Feb 15. Cancer Discov. 2019. PMID: 30770389 Free PMC article. Review.
Toward Minimal Residual Disease-Directed Therapy in Melanoma.
Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, Karras P, Brown D, Chang YH, Debiec-Rychter M, Adriaens C, Radaelli E, Wolter P, Bechter O, Dummer R, Levesque M, Piris A, Frederick DT, Boland G, Flaherty KT, van den Oord J, Voet T, Aerts S, Lund AW, Marine JC. Rambow F, et al. Cell. 2018 Aug 9;174(4):843-855.e19. doi: 10.1016/j.cell.2018.06.025. Epub 2018 Jul 12. Cell. 2018. PMID: 30017245 Free article.
Selumetinib: First Approval.
Markham A, Keam SJ. Markham A, et al. Drugs. 2020 Jun;80(9):931-937. doi: 10.1007/s40265-020-01331-x. Drugs. 2020. PMID: 32504375 Review.
Allosteric small-molecule kinase inhibitors.
Wu P, Clausen MH, Nielsen TE. Wu P, et al. Pharmacol Ther. 2015 Dec;156:59-68. doi: 10.1016/j.pharmthera.2015.10.002. Epub 2015 Oct 24. Pharmacol Ther. 2015. PMID: 26478442 Review.
Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.
Salama AKS, Li S, Macrae ER, Park JI, Mitchell EP, Zwiebel JA, Chen HX, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Armstrong DK, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Salama AKS, et al. J Clin Oncol. 2020 Nov 20;38(33):3895-3904. doi: 10.1200/JCO.20.00762. Epub 2020 Aug 6. J Clin Oncol. 2020. PMID: 32758030 Free PMC article.
MEK and the inhibitors: from bench to bedside.
Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. Akinleye A, et al. J Hematol Oncol. 2013 Apr 12;6:27. doi: 10.1186/1756-8722-6-27. J Hematol Oncol. 2013. PMID: 23587417 Free PMC article. Review.
Trametinib in metastatic melanoma.
Chopra N, Nathan PD. Chopra N, et al. Expert Rev Anticancer Ther. 2015;15(7):749-60. doi: 10.1586/14737140.2015.1060127. Expert Rev Anticancer Ther. 2015. PMID: 26107021 Review.
Systemic Therapies for Advanced Melanoma.
Bomar L, Senithilnathan A, Ahn C. Bomar L, et al. Dermatol Clin. 2019 Oct;37(4):409-423. doi: 10.1016/j.det.2019.05.001. Epub 2019 Jul 10. Dermatol Clin. 2019. PMID: 31466582 Review.
821 results